Step-by-step guide to getting a GLP-1 prescribed online in 2026: eligibility self-screen, the three pathways (insurance, branded cash-pay, compounded cash-pay), pharmacy verification, and how PlexusDx Weight Management Protocols handle the telehealth pathway in all 50 states with no membership fee.

Your GLP-1 protein target is 1.0–1.5 g/kg/day during active weight loss — meaningfully above the 0.8 g/kg RDA. This guide gives you the math, per-meal distribution, nausea-day food list, and where the PlexusDx Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 protocols sit relative to those targets.

Hit a GLP-1 plateau on semaglutide or tirzepatide? Walk the 7-step diagnostic, the dose-escalation playbook, the semaglutide-to-tirzepatide switch decision, GLP-Squared dual-compound therapy for resistant cases, and the GLP1R/GIPR genetic angle that explains why population-average titration fails some patients.

FDA labels list hair loss in 3% of Wegovy and 4–5% of Zepbound users, but the real trigger is rapid weight loss producing telogen effluvium — a reversible 6–12 month shedding pattern. This guide covers the FDA evidence, the timeline you can plan around, why women report it more often, the genetic variants behind GLP-1 response, and how a slower-titration PlexusDx protocol plus the Precision Peptide Genetic Test reduces risk before week one.

FDA-labeled BMI thresholds for Wegovy and Zepbound, the comorbidity list that opens the 27–29.9 tier, and where PlexusDx Weight Management Protocols fit when the prescribing clinician — not a calculator — makes the eligibility call.

The best tirzepatide online in 2026 depends on insurance status, format, and whether you want a genetic baseline guiding titration. Compare MEDVi, YUCCA Health, Willow, Eden, and TrimRx against PlexusDx Tirzepatide Injection ($289/mo) and Tirzepatide Oral ($349/mo), with the optional Precision Peptide Genetic Test for pathway-level context.

Practical, food-by-food playbook for managing Zepbound (tirzepatide) nausea: what to eat in the first 24 hours after your shot, what to drink, what to avoid, when to call your doctor, and how genetic variants in GIPR, and gastric-emptying genes explain why some patients are far more sensitive than others. Includes how PlexusDx Tirzepatide Injection ($289/mo) and Tirzepatide Oral ($349/mo) compounded protocols, paired with the Precision Peptide Genetic Test, let your clinician anchor titration to your biology.

Honest review of Willow GLP-1 patient reviews, pricing ($299-$549/mo), compounded sourcing, and how PlexusDx Weight Management Protocols compare on cost, formulary, state availability, and the optional Precision Peptide Genetic Test for individualized dose decisions.

Which Wegovy providers actually let you swipe your FSA card at checkout vs. file for reimbursement? NovoCare Pharmacy and LifeMD verified for direct-card payment; Hims, Hers, and Ro are reimbursement-first. Plus what to do when your FSA balance runs out and PlexusDx Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan becomes the flat cash-pay reframe.

TrimRx vs Ro vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication, oral pill options, safety oversight, and PlexusDx's optional genetic-baseline test. Includes a four-question decision frame and pricing across PlexusDx Microdose GLP-1, Semaglutide Injection, Tirzepatide Injection, and GLP-Squared.

The standard FDA tirzepatide dosing schedule moves through six weekly dose levels: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, with at least four weeks between steps. This guide walks the week-by-week ladder for both injection and oral compounded tirzepatide, the milligram-to-unit conversions for compounded vials, missed-dose rules, and how the GIPR rs1800437 genetic variant can inform titration pace before week one.

PA stuck on Wegovy, Zepbound, or Foundayo? The bridge options that won’t complicate your approval — LillyDirect from $299/mo, NovoCare from $149/mo, and the PlexusDx Microdose GLP-1 Protocol at $129/mo flat with no commitment.

Synergy Rx GLP-1 review: real maintenance pricing, compounded vs branded medication source, cash-pay alternatives, and how PlexusDx Weight Management Protocols compare on price, delivery format, and genetic baseline.

SkinnyRx vs MEDVi vs PlexusDx compared on cost, formats, oversight, FDA warning letters, and genetic personalization — with PlexusDx Microdose at $129/mo flat as the cheapest cash-pay tier and the Precision Peptide Genetic Test as the only genetic baseline in the three-way comparison.

An honest, verified review of Skinny Rx tirzepatide tablets — the $299/month buccal-dissolve compounded product, the February 2026 FDA warning letter, and the actual evidence picture for any oral tirzepatide formulation — with a feature-by-feature comparison to PlexusDx Tirzepatide Oral Protocol ($349/mo, 5mg to 25mg daily across seven dose levels) as the cash-pay alternative.

SHED vs Ro vs PlexusDx for cash-pay GLP-1 weight loss in 2026 — compounded vs FDA-approved branded, real annual cost math, insurance posture, format flexibility, and why genetics inform PlexusDx dose decisions before week one.

FSA eligibility for semaglutide is governed by IRS Publication 502, not by individual provider marketing. We walk through the rule, the two payment paths (direct card at checkout vs reimbursement), how PlexusDx handles FSA-issued cards, and how compounded vs FDA-approved status affects substantiation.

Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes only — not for weight loss. See the real PIONEER weight numbers, the ~$998/month cash price, why insurance rarely covers off-label use, and how PlexusDx Semaglutide Oral ($289/mo+) and the Microdose GLP-1 Protocol ($129/mo) compare on cost and dose flexibility.

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129/mo to $349/mo) compare for someone who needs an option today rather than in 2028.

Is oral tirzepatide FDA approved? No — only injectable Mounjaro and Zepbound are. Here's what compounded oral tirzepatide is, how PlexusDx Tirzepatide Oral ($349/mo) fits, and the safety considerations that apply to both.

Oral semaglutide vs injectable semaglutide in 2026: Rybelsus, the new Wegovy pill, Ozempic, and Wegovy injection compared on dose, bioavailability, effectiveness, and cost — plus where PlexusDx Semaglutide Oral ($289/mo+), Semaglutide Injection ($189/mo), and Microdose GLP-1 Protocol ($129/mo flat) fit as cash-pay alternatives covering both pill and shot formats.

MEDVi vs TrimRx vs PlexusDx in 2026: real cash-pay GLP-1 pricing, compounded vs branded, multi-month upfront vs month-to-month, and where genetic testing changes the dose conversation before week one.

MEDVi vs Ro vs PlexusDx for cash-pay GLP-1 weight loss: real annualized cost math, compounded vs FDA-approved branded, safety considerations, and where genetic baselining changes the dose decision before week one.

MEDVi, Remedy Meds, and PlexusDx all dispense compounded semaglutide and tirzepatide — but the annualized cost, billing cadence, and clinical-oversight model differ in ways the landing pages don't show. This guide walks the real numbers, the September 2025 FDA warning-letter context, and where PlexusDx Weight Management Protocols ($129/mo to $349/mo) plus the Precision Peptide Genetic Test fit relative to both.

MEDVi vs Lilly Direct vs PlexusDx in 2026: all-inclusive compounded telehealth, FDA-approved Zepbound at self-pay vial pricing, and a genetics-anchored compounded protocol. Real 12-month math, the 45-day refill trap, and where each fits.

MEDVi vs Hims vs PlexusDx in 2026: MEDVi at $299/mo ongoing month-to-month with no contract, Hims at $199/mo gated behind a $1,194 six-month prepayment, and PlexusDx Weight Management Protocols from $129/mo with no upfront commitment and an optional Precision Peptide Genetic Test for genetic-guided GLP-1 dosing.

MEDVi vs Hers vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication source, tirzepatide availability across all three, cancellation and refund policy differences, and where the Precision Peptide Genetic Test fits when GLP-1 response varies by GIPR, FTO, MC4R, and TCF7L2 variants.

MEDVi vs Gala GLP-1 vs PlexusDx compared on verified 2026 pricing, compounded vs FDA-approved status, cancellation rules, and where a genetic baseline changes the dose decision before week one.

MEDVi’s ongoing compounded semaglutide rate is $299/month, with multi-month prepaid plans also offered. We reconcile MEDVi’s pricing against PlexusDx Semaglutide Injection ($189/mo) and Semaglutide Oral ($289/mo) on a 12-month total-cost basis — with the genetic baseline MEDVi doesn’t offer.

MEDVi sells two different oral GLP-1 products under one banner: a compounded semaglutide tablet priced after the intake questionnaire and a Wegovy pill route on a separate membership plus medication. We unpack the pricing, the FDA regulatory status, the 72-hour cancellation rule, and where PlexusDx Semaglutide Oral ($289/mo+) and Microdose GLP-1 Protocol ($129/mo flat) fit for cash-pay readers who want a non-injection GLP-1.